Beat AML主试验:前瞻性基因组分析指导急性髓系白血病精准治疗
Beat AML主试验前瞻性纳入≥60岁疑似AML患者,旨在7天内提供细胞遗传学和突变数据并据此分配亚研究治疗。共入组487例,395例符合条件,374例(94.7%)在7天内完成分析并中心分配亚研究,224例(56.7%)入组亚研究。亚研究组30天死亡率更低且总生存显著优于选择标准治疗者,表明7天内精准医学治疗策略可行。
要点
- ≥60岁AML患者可在7天内完成基因组分析并指导治疗分配。
- 入组亚研究者30天死亡率更低,总生存显著优于标准治疗。
- 精准医学策略未增加早期死亡或不利影响总生存。
核心结论
- 在AML中实施7天内精准医学治疗策略可行,不增加早期死亡且不 adverse 影响总生存。
研究设计与样本
- 前瞻性入组≥60岁疑似AML患者487例,395例符合条件,中位年龄72岁(范围60-92岁;38%≥75岁)。
- 旨在样本接收后7天内提供细胞遗传学和突变数据,并根据优势克隆分配至亚研究。
主要发现
- 374例(94.7%)在7天内完成遗传学和细胞遗传学分析并中心分配至Beat AML亚研究,224例(56.7%)入组亚研究。
- 171例选择标准治疗(103例)、研究性治疗(28例)或姑息治疗(40例);9例在治疗分配前死亡。
- 亚研究与标准治疗组在人口学、实验室和分子特征上无显著差异。
- 亚研究组30天死亡率更低,总生存显著长于选择标准治疗者。
关键数值与推荐
- 标准治疗为阿糖胞苷+柔红霉素(7+3或等效方案)或低甲基化剂。
临床怎么用
- 对≥60岁AML患者,可在7天内整合基因组数据用于治疗决策,无需延迟治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults, AML confers an adverse outcome1,2. AML originates from a dominant mutation, then acquires collaborative transformative mutations leading to myeloid transformation and clinical/biological heterogeneity. Currently, AML treatment is initiated rapidly, precluding the ability to consider the mutational profile of a patient's leukemia for treatment decisions. Untreated patients with AML ≥ 60 years were prospectively enrolled on the ongoing Beat AML trial (ClinicalTrials.gov NCT03013998 ), which aims to provide cytogenetic and mutational data within 7 days (d) from sample receipt and before treatment selection, followed by treatment assignment to a sub-study based on the dominant clone. A total of 487 patients with suspected AML were enrolled; 395 were eligible. Median age was 72 years (range 60-92 years; 38% ≥75 years); 374 patients (94.7%) had genetic and cytogenetic analysis completed within 7 d and were centrally assigned to a Beat AML sub-study; 224 (56.7%) were enrolled on a Beat AML sub-study. The remaining 171 patients elected standard of care (SOC) (103), investigational therapy (28) or palliative care (40); 9 died before treatment assignment. Demographic, laboratory and molecular characteristics were not significantly different between patients on the Beat AML sub-studies and those receiving SOC (induction with cytarabine + daunorubicin (7 + 3 or equivalent) or hypomethylation agent). Thirty-day mortality was less frequent and overall survival was significantly longer for patients enrolled on the Beat AML sub-studies versus those who elected SOC. A precision medicine therapy strategy in AML is feasible within 7 d, allowing patients and physicians to rapidly incorporate genomic data into treatment decisions without increasing early death or adversely impacting overall survival.
引用
- Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020. PMID: 33106665. doi:10.1038/s41591-020-1089-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。